Browsing Tag
intranasal drug delivery
5 posts
How intranasal neurosteroids may change emergency care timing in mild traumatic brain injury
Can ONP-002 change concussion care timing? Discover how Oragenics, Inc. is targeting early intervention in mTBI treatment.
The $9bn concussion treatment question Oragenics hopes ONP-002 can answer
Oragenics launches Phase IIa trial of ONP-002 for concussion. Discover whether this therapy could unlock the $9B traumatic brain injury market.
How intranasal delivery could reshape Clearmind Medicine Inc.’s MEAI development strategy in addiction
Find out how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape addiction drug development risk and execution.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
What makes Aptar Pharma’s latest nasal drug delivery bet a potential market disruptor?
Aptar Pharma teams up with Dianosic to advance a bioresorbable nasal scaffold platform for chronic sinus and rhinitis care. Find out how this could reshape treatment.